Regulus Therapeutics (RGLS) Shares Up 5.1%

Regulus Therapeutics Inc (NASDAQ:RGLS) shares shot up 5.1% during mid-day trading on Monday . The stock traded as high as $1.31 and last traded at $1.24. 1,561,500 shares traded hands during mid-day trading, an increase of 50% from the average session volume of 1,037,825 shares. The stock had previously closed at $1.18.

Several brokerages have recently issued reports on RGLS. Leerink Swann started coverage on Regulus Therapeutics in a research report on Friday, January 5th. They issued an “outperform” rating and a $2.00 target price for the company. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Zacks Investment Research downgraded Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th. Finally, Wedbush restated an “outperform” rating and issued a $4.00 price target on shares of Regulus Therapeutics in a research note on Monday, December 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $2.46.

The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41. The company has a market cap of $121.63, a P/E ratio of -0.84 and a beta of 1.55.

Institutional investors and hedge funds have recently modified their holdings of the business. Quantitative Investment Management LLC purchased a new stake in Regulus Therapeutics during the 2nd quarter valued at $103,000. GSA Capital Partners LLP purchased a new stake in Regulus Therapeutics during the 2nd quarter valued at $139,000. Royal Bank of Canada boosted its stake in Regulus Therapeutics by 12.1% during the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in Regulus Therapeutics during the 3rd quarter valued at $347,000. Finally, Goldman Sachs Group Inc. boosted its stake in Regulus Therapeutics by 189.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 240,890 shares during the last quarter. Institutional investors and hedge funds own 59.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/10/regulus-therapeutics-rgls-shares-up-5-1.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

What are top analysts saying about Regulus Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regulus Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit